To explore the economic and patient safety consequences of errors with specimens, researchers performed a systematic review of previously published studies on the frequency of error rates, various treatment modalities and costs.
They found that out of roughly 806,000 prostate biopsy procedures performed annually in the United States, 20,300 involved a specimen switch or contamination and nearly 4,600 patients were estimated to have received a false-positive or false-negative diagnosis based on the wrong specimen.
All total, the misdiagnoses result in approximately $880 million in unnecessary healthcare expenditures each year, according to the study.
More articles on medical errors:
Blood pressure management apps could be error-prone, dangerous
What drives a patient to report a medical error?
23% of Massachusetts adults experienced a medical error, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.